Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)

被引：16

作者：

Maeda, Haruka ^{[1
,2
]}

Saito, Nobuo ^{[3
]}

Igarashi, Ataru ^{[4
,5
]}

Ishida, Masayuki ^{[6
]}

Suami, Kazuya ^{[7
]}

Yagiuchi, Ai ^{[7
]}

Kimura, Yuya ^{[8
]}

Komino, Masaru ^{[8
]}

Arai, Hiromi ^{[8
]}

Morikawa, Toru ^{[9
]}

Motohashi, Iori ^{[10
]}

Miyazawa, Rei ^{[10
]}

Moriyama, Tetsu ^{[11
]}

Kamura, Hiroshi ^{[12
]}

Terada, Mayumi ^{[13
]}

Kuwamitsu, Osamu ^{[14
]}

Hayakawa, Tomoichiro ^{[15
]}

Sando, Eiichiro ^{[16
,17
]}

Ohara, Yasuji ^{[18
]}

Teshigahara, Osamu ^{[19
]}

Suzuki, Motoi ^{[20
]}

Morimoto, Konosuke ^{[1
]}

机构：

[1] Nagasaki Univ, Inst Trop Med, Dept Resp Infect, 1-12-4 Sakamoto, Nagasaki 8528523, Japan

[2] Nagasaki Univ, Dept Clin Trop Med, Grad Sch Biomed Sci, Nagasaki, Japan

[3] Oita Univ, Fac Med, Dept Microbiol, Oita, Japan

[4] Yokohama City Univ, Unit Publ Hlth & Prevent Med, Sch Med, Yokohama, Kanagawa, Japan

[5] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Econ & Outcomes Res, Tokyo, Japan

[6] Chikamori Hosp, Kochi, Japan

[7] Nagoya Ekisaikai Hosp, Nagoya, Aichi, Japan

[8] Saiseikai Kurihashi Hosp, Saitama, Japan

[9] Nara City Hosp, Nara, Japan

[10] Kawasaki Municipal Tama Hosp, Kawasaki, Kanagawa, Japan

[11] Moriyama Mem Hosp, Tokyo, Japan

[12] Loco Clin Nakameguro, Tokyo, Japan

[13] Nijigaoka Hosp, Nagasaki, Japan

[14] Gohongi Clin, Tokyo, Japan

[15] Hayakawa Internal Med Clin, Fukuoka, Japan

[16] Kita Fukushima Med Ctr, Fukushima, Japan

[17] Fukushima Med Univ, Fukushima, Japan

[18] Takagi Hosp, Nagoya, Aichi, Japan

[19] Mizuho St Clin, Nagoya, Aichi, Japan

[20] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan

来源：

CLINICAL INFECTIOUS DISEASES | 2022年 / 75卷 / 11期

关键词：

SARS-CoV-2; COVID-19; vaccine effectiveness; Delta; Japan;

D O I：

10.1093/cid/ciac292

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This multicenter test-negative case-control study showed messenger RNA COVID-19 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan during July-September 2021: 88.7% among people aged 16-64 years and 90.3% among those aged >= 65 years. Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. Methods We conducted a multicenter test-negative case-control study in patients aged >= 16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (>= 90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed. Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses >= 14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged >= 65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months. Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide.

引用

页码：1971 / 1979

页数：9

共 50 条

[1] Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Terada, Mayumi
Ito, Takayasu
Ikeda, Hideko
Kamura, Hiroshi
Motohashi, Iori
Kimura, Yuya
Komino, Masaru
Arai, Hiromi
Kuwamitsu, Osamu
Akuzawa, Nobuhiro
Sando, Eiichiro
Morikawa, Toru
Imura, Haruki
Inoue, Hiroki
Hayakawa, Tomoichiro
Teshigahara, Osamu
Ohara, Yasuji
Suzuki, Motoi
Morimoto, Konosuke
EXPERT REVIEW OF VACCINES, 2023, 22 (01) : 288 - 298
[2] Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, SubbaRao, V
Dallavalasa, Siva
Basavaraju, Chaithanya G.
Rao, Vinay Kumar
Chikkahonnaiah, Prashanth
Madhunapantula, SubbaRao, V
Veeranna, Ravindra P.
VACCINES, 2022, 10 (10)
[3] Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
Swift, Melanie D.
Breeher, Laura E.
Tande, Aaron J.
Tommaso, Christopher P.
Hainy, Caitlin M.
Chu, Haitao
Murad, M. Hassan
Berbari, Elie F.
Virk, Abinash
CLINICAL INFECTIOUS DISEASES, 2021, 73 (06) : E1376 - E1379
[4] Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Terada, Mayumi
Masuda, Shingo
Osawa, Ryosuke
Hosokawa, Naoto
Nakashima, Kei
Kamura, Hiroshi
Imura, Haruki
Inoue, Hiroki
Matsuzaka, Suguru
Sugimoto, Yukihiro
Kuwamitsu, Osamu
Motohashi, Iori
Morikawa, Toru
Oda, Rentaro
Hoshina, Yuiko
Matono, Takashi
Teshigahara, Osamu
Sando, Eiichiro
Asami, Sadaharu
Kudo, Satoshi
Akizuki, Noboru
Muto, Yoshikazu
Hayakawa, Tomoichiro
Kishaba, Tomoo
Ohara, Yasuji
Kubo, Yoshinao
Suzuki, Motoi
Morimoto, Konosuke
EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 213 - 225
[5] Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants
Ghavidel, Afshin Abdi
Rojhannezhad, Mahbubeh
Kazemi, Bahram
Bandehpour, Mojgan
IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2021, 20 (06) : 647 - 671
[6] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
O'Leary, Valerie Brid
Ovsepian, Saak Victor
TRENDS IN GENETICS, 2020, 36 (11) : 892 - 893
[7] Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Zhang, Chao
Zhou, Chenliang
Shi, Li
Liu, Ge
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (10) : 2366 - 2369
[8] Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, Simone
Kratochvil, Sven
Kato, Yu
Vadivelu, Kumaran
Rappuoli, Rino
PHARMACOLOGICAL REVIEWS, 2022, 74 (01) : 313 - 339
[9] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review
Wei Feng
Wei Zong
Feng Wang
Shaoqing Ju
Molecular Cancer, 19
[10] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review
Feng, Wei
Zong, Wei
Wang, Feng
Ju, Shaoqing
MOLECULAR CANCER, 2020, 19 (01)

← 1 2 3 4 5 →